



CODEX Clinical Outcomes Databases

Alzheimer's Disease (AD)



Curated clinical trial data for earlier, confident decisions

Certara's Clinical Trial Outcomes Database (CODEX) is an expertly curated database of clinical trial data for marketed and pipeline drugs, covering 8 therapeutic areas and 70+ indications. It includes structured and unstructured data that can be downloaded and integrated with internal datasets to support modeling and simulation, enabling earlier, more confident drug development decisions.

With CODEX, you can:



Identify the right trial populations

analyze clinical data to identify target populations for new studies.



Improve study design

refine sample size calculations to reduce costs and increase success rates.



Strengthen regulatory strategy

review integrated summaries of safety and efficacy (ISS/ISE) for similar products to inform regulatory approval strategies.



Demonstrate commercial viability

run economic models to generate additional data points that can be used to demonstrate value to payers and in competitive pricing assessments.

Model-based meta-analysis (MBMA)

MBMA leverages CODEX databases and pharmacology models to increase development productivity, quantitatively inform portfolio decisions, and improve clinical trial success. It optimizes trial design, including timing, endpoints, and dosing, as well as competitive landscape assessment. MBMA also bridges across studies, allowing comparison of treatments and patient populations that may not have been evaluated within the same trial.



~417 studies

Key Efficacy & Biomarker Endpoints (MMSE, ADAScog-11, NPI-12, CDR-sob, and ADCS-ADL-23)



~131,289 patients

All systemic or novel pharmacological treatments with primary focus on disease modifying & Symptomatic treatments



~93,212

Longitudinal Data Points – Format available in Excel and CODEX (Clinical Outcomes Database Explorer)

A comprehensive repository of AD clinical outcomes

The CODEX Alzheimer's Disease (AD) Database provides utility across the drug development continuum to inform critical decisions that determine not only a drug's successful performance during a trial, but also a drug's profile within a competitive landscape. The AD Database highlighted here is curated to document clinical efficacy and biomarker information from all randomized placebo and active controlled trials in Alzheimer's Disease patients. Trials found in this database also include washout designs and add on designs.

Treatment	Class	Studies
donepezil	cholinesterase inhibitor	55
memantine	NMDA antagonist	26
rivastigmine	cholinesterase inhibitor	23
galantamine	cholinesterase inhibitor	20
bapineuzumab	Abeta	12
rivastigmine transdermal	cholinesterase inhibitor	12
tacrine	cholinesterase inhibitor	12
ponezumab	Abeta	11
solanezumab	Abeta	11

Table 1. The top 9 drugs in the CODEX AD database




Figure 1. Snapshot of select treatments; ADAS-cog-11 time course




Figure 2. MMSE time course for trials with donepezil

Discover how CODEX can empower more confident decisions.

To learn more or request a demo, visit certara.com/codex

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

Visit certara.com | Copyright ©2026 Certara. All rights reserved.